Form 4: Adaptive Biotechnologies COO Sells Shares

Adaptive Biotechnologies' President and COO, Julie Rubinstein, executed pre-planned option exercises and subsequent sales of company common stock over three days in March 2026.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), engaged in a series of transactions involving company common stock.
• On March 24, 25, and 26, 2026, Rubinstein acquired 14,722 shares of common stock each day through the exercise of stock options at a price of $7.27 per share.
• Concurrently, on each of those three days, Rubinstein disposed of 19,060 shares of common stock.
• The sale prices were a weighted average of $13.70 on March 24, $14.27 on March 25, and $14.12 on March 26.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Rubinstein on November 18, 2025.
• Following these transactions, Rubinstein's direct beneficial ownership of common stock decreased from 496,628 shares (after the first acquisition) to 468,892 shares (after the final sale).
• The stock options exercised were fully vested and exercisable, with an expiration date of February 7, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sales are based on new, adverse information. It primarily reflects personal financial planning.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-scheduled sales not based on immediate, non-public information, which is a positive for corporate governance.
• The exercise of stock options at $7.27 per share, followed by sales at significantly higher prices (ranging from $13.70 to $14.27), demonstrates the financial benefit realized by the insider from previously granted equity awards.

Negatives

• The net effect of the transactions was a reduction in the reporting person's direct beneficial ownership of common stock, as more shares were sold than acquired through option exercise each day.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity alignment with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals about management's perception of future company prospects. While sales under a Rule 10b5-1 plan are generally viewed as less indicative of a negative outlook compared to unscheduled sales, they still represent a reduction in an executive's direct equity exposure. In the biotechnology sector, executive compensation often includes significant equity components, making such transactions a routine part of personal financial planning.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider selling with some caution, although the 10b5-1 plan provides a mitigating context. The reduction in direct ownership could be seen as a slight decrease in alignment.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Julie Rubinstein, Beneficial Ownership